← Browse by Condition
Medical Condition

locally advanced or metastatic solid tumors

Total Trials
3
Recruiting Now
3
Trial Phases
Phase 2, Phase 1, Phase 2, Phase 1

ClinicalMetric tracks all active clinical trials for locally advanced or metastatic solid tumors sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — locally advanced or metastatic solid tumors Clinical Trials

How many clinical trials are currently recruiting for locally advanced or metastatic solid tumors?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for locally advanced or metastatic solid tumors, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for locally advanced or metastatic solid tumors?
locally advanced or metastatic solid tumors research spans Phase 1 (2 trials), Phase 2 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a locally advanced or metastatic solid tumors clinical trial?
Eligibility criteria for locally advanced or metastatic solid tumors trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
2
Phase 2
2
Top Sponsors
MediLink Therapeutics (Suzhou) Co., Ltd. 1 trial
Xuanzhu Biopharmaceutical Co., Ltd. 1 trial
Antengene Therapeutics Limited 1 trial

Recruiting Clinical Trials

NCT07202364 Phase 2
Recruiting

A Study of YL202 in Patients With Advanced Solid Tumors

Enrollment
100 pts
Location
China
Sponsor
MediLink Therapeutics (Suzhou)...
View Trial →
NCT04996121 Phase 1, Phase 2
Recruiting

A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors

Enrollment
360 pts
Location
China
Sponsor
Xuanzhu Biopharmaceutical Co.,...
View Trial →
NCT05205109 Phase 1
Recruiting

A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG 037 Monotherapy and Combination Therapy With Pembrolizumab in Patients With Advanced Solid Tumors

Enrollment
98 pts
Location
Australia, China
Sponsor
Antengene Therapeutics Limited
View Trial →
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology